Cagrilintide
Reviewed by Fat Man in the Arena · Updated March 2026
Key Takeaway
Cagrilintide is a long-acting amylin analog being developed by Novo Nordisk, studied in combination with semaglutide (CagriSema) for enhanced weight loss.
How it works
Mimics the hormone amylin, which is co-secreted with insulin. Reduces appetite through hypothalamic signaling and slows gastric emptying via a pathway independent of GLP-1.
Benefits
- Complementary mechanism to GLP-1 agonists
- CagriSema combination shows greater weight loss than semaglutide alone
Side effects
- Nausea
- Injection site reactions
Dosing protocol
Typical Dose
2.4 mg weekly (in combination)
Frequency
Once weekly
Studied primarily in combination with semaglutide (CagriSema).
Related peptides
Weekly peptide research updates
New studies, GLP-1 news, protocol insights, and weight loss data — delivered every week. Free. No spam.
Medical Disclaimer: This content is for informational and educational purposes only. It is not intended as medical advice or a substitute for professional medical consultation, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide protocol.